Company has raised $112m in order to develop therapies for central nervous system disorders
News
Protalix and Chiesi gain positive opinion for pegunigalsidase alfa
The therapy becomes the first pegylated enzyme for the treatment of adult patients with Fabry disease
Moderna opts for Oxfordshire in quest for innovation
Vaccines developed at the facility will cover a wide range of respiratory diseases
Sequana Medical announces positive results for DSR 2.0 candidate
Extensive phase 1 clinical trial evaluates safety of treatment among peritoneal patients
Amniotics’ PulmoStem receives positive safety data
Treatment is a lung-specific stem cell therapy designed for hospitalised patients with respiratory infections
Vital update for Valneva’s COVID-19 vaccine
European Medicines Agency has issued a positive opinion for the use of VLA2001 among certain adults
Positive results from Poolbeg Pharma’s human challenge trial
Candidate POLB 001 demonstrates potential in treating multiple influenza conditions
Industry research boost from University of Aberdeen
The programme will support new European and national strategies to reduce exposure to hazardous chemicals
New ABPI proposals provide NHS and industry impetus
Pharma’s offer includes a yearly £1bn boost to the NHS and a new investment facility
Hope for Parkinson’s disease and Lewy body dementia patients
Research into modified RNA messages could help treat diseases and develop new therapies
OKYO Pharma reveals update on dry eye disease candidate
Phase 2 study of OK-101 will commence soon as company hopes drug will provide unmet need
Positive CHMP opinion for Janssen’s AKEEGA
If approved company’s prostate cancer therapy will be the first dual-action tablet available in EU
CN Bio launches single-organ higher throughput system PhysioMimix
Tech was created to overcome adoption obstacles currently reducing the use of predictive human liver models
PBD Biotech broadens patent for tuberculosis diagnostic
Africa-based trials for blood test which detects risk of disease progression are due to begin
Merck delivers vital data on evobrutinib
Treatment is an BTK inhibitor and has demonstrated a sound safety and tolerability profile
